Plain-English translation of NCT07292168 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called OM-RCA-01, which is a monoclonal antibody designed to block a protein called FGFR1 that helps cancer cells grow. The study will enroll about 58 patients with advanced cancers (kidney, lung, breast, prostate, or head and neck cancer) that have this specific protein marker. Researchers want to see if this medication is safe and whether it can slow or stop cancer growth.
Right now, there are very few treatment options specifically designed to target the FGFR1 protein in solid tumors. This trial exists to find out whether this new medication can offer hope to patients whose cancers have stopped responding to standard treatments and have limited other options.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication through a vein every 2 weeks until your cancer progresses or the side effects become unacceptable. You would need regular blood tests and imaging scans to monitor how your cancer is responding and check for any side effects. The study will continue to follow your health and track your cancer's progress over time.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Russia